九年前，莉萨·海恩斯（Lisa Haines）悲观地得知，她之前通过化疗抑制的肺癌又复发了。正当这名患者准备接受现实，主治医生推荐了一种免疫疗法，Opdivo。

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

当乳腺癌扩散到大脑时，会导致严峻的后果，患者通常只有六个月的生命。临床统计表明，HER2阳性乳腺癌女性在多达55％的病例中倾向于发生脑转移。针对脑转移的乳腺癌细胞，目前化学疗法药物通常无效，因为它们无法穿越血脑屏障。

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug ...

"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...

A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Monoclonal antibodies—treatments developed by cloning a cell that makes an antibody—could help provide an answer to the ...

Live-cell microscopy routinely provides massive amount of time-lapse images of complex cellular systems under various physiological or therapeutic conditions. However, this wealth of data remains ...